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Interleukin (IL) 35 is a novel immunosuppressive heterodimeric cytokine in IL-12 family.
Whether and how IL-35 regulates ischemia-induced angiogenesis in peripheral artery
diseases are unrevealed. To fill this important knowledge gap, we used loss-of-function,
gain-of-function, omics data analysis, RNA-Seq, in vivo and in vitro experiments, and we
have made the following significant findings: i) IL-35 and its receptor subunit IL-12RB2,
but not IL-6ST, are induced in the muscle after hindlimb ischemia (HLI); ii) HLI-induced
angiogenesis is improved in Il12rb2−/− mice, in ApoE−/−/Il12rb2−/− mice compared to
WT and ApoE−/− controls, respectively, where hyperlipidemia inhibits angiogenesis in vivo
and in vitro; iii) IL-35 cytokine injection as a gain-of-function approach delays blood
perfusion recovery at day 14 after HLI; iv) IL-35 spares regenerative angiogenesis at the
late phase of HLI recovery after day 14 of HLI; v) Transcriptome analysis of endothelial cells
(ECs) at 14 days post-HLI reveals a disturbed extracellular matrix re-organization in IL-35-
injected mice; vi) IL-35 downregulates three reactive oxygen species (ROS) promoters
and upregulates one ROS attenuator, which may functionally mediate IL-35 upregulation
of anti-angiogenic extracellular matrix proteins in ECs; and vii) IL-35 inhibits human
microvascular EC migration and tube formation in vitro mainly through upregulating
anti-angiogenic extracellular matrix-remodeling proteins. These findings provide a novel
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insight on the future therapeutic potential of IL-35 in suppressing ischemia/inflammation-
triggered inflammatory angiogenesis at early phase but sparing regenerative angiogenesis
at late phase.
Keywords: IL-35, angiogenesis, ischemia and hypoxia, endothelial cells, IL-12Rb2
INTRODUCTION
Peripheral arterial disease (PAD) is a vascular pathology where
narrowed arteries reduce blood flow to the peripheral extremities
and organs such as legs, arms, and head. The most common
symptom of PAD is leg pain, particularly when walking. PAD is
highly associated with coronary artery disease and stroke (1),
which are the leading causes of death worldwide. They are caused
by atherosclerosis, where the plaques build-up in the artery wall,
a common condition in the aging population. It is estimated that
more than 200 million people have PAD worldwide (1).
Although the current gold standard treatment for advanced
PAD patients is surgical revascularization, there are no
effective therapies for many patients with advanced conditions
who are not candidates for surgery (2). Also, better recovery
from surgical revascularization largely relies on angiogenesis
in adjacent ischemic tissue. Thus, novel therapies such as
pro-angiogenic therapy to improve neovascularization are
urgently desired.
Since Dr. Vignali’s team reported the contribution of novel
cytokine interleukin-35 (IL-35) to CD4+Foxp3+ regulatory cell
(Treg) function in 2007 (3), significant progress has been made
with 629 publications on PubMed. We reported that IL-35 is a
new responsive heterodimeric anti-inflammatory cytokine (4).
IL-35 belongs to the IL-12 cytokine family and is potent in
inhibit ing various inflammatory diseases including
lipopolysaccharide (LPS)-induced lung inflammation, human
aortic endothelial cell (HAEC) activation (5), atherogenic lipids
lysophosphatidylcholine (LPC) (6–8) -induced HAEC activation
and atherosclerosis (9) but sparing innate immune memory
(trained immunity) in HAEC (8, 10–12) as we reported. IL-35
a-chain p35 (encoded by IL12A) is shared with IL-12; and b-
chain EBI3 (encoded by Epstein–Barr virus-induced 3, EBI3) is
shared with IL-27 and IL-39. IL-35 receptor (IL35R) subunit IL-
12Rb2 (encoded by IL12RB2) is shared with IL-12 receptor; and
IL35R subunit IL-6 signal transducer (IL6ST, gp130) is shared
with IL-27 and IL-39 receptors. In addition, EBI3 receptor IL6ST
is also shared with IL-6 superfamily, where the IL-12 family
belongs. IL-35 signaling is unconventional because it has
multiple forms of receptors and presents cell-specificity, as we
reviewed (13). It can bind not only to heterodimeric receptor IL-
6ST-IL-12Rb2, but also two homodimers such as: i) IL-6ST-IL-
6ST, and ii) IL-12Rb2-IL-12Rb2, which then activates signal
transducer and activator of transcription 1 (STAT1) and STAT4
in Treg (13). The same study also shows that maximal anti-
inflammatory function requires the heterodimeric receptor (5).
However, the following study shows that in regulatory B cells
(Breg), IL-35 signals through a heterodimer of IL-12Rb2 and IL-
27Ra and activates STAT1 and STAT3 (14). Unlike other
members in the IL-12 family that are secreted mainly by
activated antigen-presenting cells (dendritic cells, monocyte/
macrophages, and B cells), IL-35 is predominantly secreted by
Treg (15) and Breg. To a less extent, it has been predicted to be
secreted by other cell types including endothelial cells (ECs) (4).
Angiogenesis is the process of new capillary formation from
pre-existing vessels. Inflammation, angiogenesis, and
extracellular matrix (ECM) remodeling are often coupled in
pathological conditions (16). Inflammation drives angiogenesis
by direct and indirect mechanisms, promoting EC proliferation,
migration, and vessel sprouting, but also by mediating
extracellular matrix remodeling and release of sequestered
growth factors, and recruitment of proangiogenic leukocyte
subsets (17). In chronic inflammation, the formation of new
blood vessels results in an increased endothelial surface area,
which further facilitates inflammatory cell migration (18) into
the inflamed tissue through vasodilatation and increased
endothelial cell permeability (19). Although ECs are the most
important cell types (20) in the angiogenic process, immune cell
infiltration is critical for angiogenesis in the early stage of
ischemia; although sustained inflammation can also lead to
delayed angiogenesis (21) or undesired vessel overgrowth (22).
Hindlimb ischemia represents a complex model with ischemia-
induced necrosis and inflammation, ischemia-induced
angiogenesis, arteriogenesis and skeletal muscle regeneration
(23). In comparison, scarless wound healing in fetuses has been
associated with a short-lived and less robust inflammatory
response (21). Thus, anti-inflammatory cytokines are key
regulators in balancing the local inflammation and promote
functional neovascularization. IL-35 is expressed in many
tumor cell lines, and promotes tumor angiogenesis and
progression (24–26). However, it has also been shown that IL-
35 over-expression increases apoptosis sensitivity and inhibits
cell proliferation in human cancer cells (27). Besides, IL-35
inhibits angiogenesis in rheumatoid arthritis, where one study
showed that IL-35 can directly inhibit human umbilical vein
endothelial cells (HUVECs) angiogenic activities (28). However,
the roles of IL-35 in angiogenesis in ischemic vascular diseases
are unrevealed.
Mechanistically, angiogenesis involves several biological
events, including extracellular matrix (ECM) degradation,
pericyte detachment, EC proliferation, migration, and
sprouting, the fusion of tip cells, lumen formation, pericyte
reattachment, ECM redeposition, and vascular remission and
stabilization. Each event requires a balance between pro-
angiogenic and anti-angiogenic factors, which is by large
mediated by ECM proteins and proteases. Integrins are
transmembrane proteins that bind to many types of ECM
proteins. They are required for focal adhesion (cell-ECM
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adhesion) formation that mechanically connects intracellular
actin bundles and the extracellular substrate (29). Focal
adhesion also bi-directionally transmits molecular signals, and
is essential for a variety of cellular activities including cell
adhesion, migration, differentiation, and survival (30). In
mammals, ECM is a highly dynamic structure composed of
~300 main proteins, including 43 collagen subunits, 36
proteoglycans, and ~200 glycoproteins (31). It provides not
only physical support for vascular integrity but also mediates
cellular functions such as proliferation and migration. On the
other side, matrix metalloproteinases (MMPs), a disintegrin and
metalloproteinases (ADAM) and ADAM with thrombospondin
motifs (ADAMTS) are the major proteases that collectively can
degrade all known ECM components. Thus, they are critical in
regulating ECM remodeling during angiogenesis.
Reactive oxygen species (ROS) play an important role in
modulating angiogenesis. Low cellular levels of ROS are usually
maintained by systems of antioxidant enzymes and their
substrates, such as thioredoxin systems (Trx1 and 2) (32). It
has been reported that cardiac-specific Trx2 knockout mice
recently demonstrated that suppression of mitochondrial ROS
can preserve cardiac function by inhibiting apoptosis signal
regulating kinase-1-mediated apoptosis (33). However,
mitochondrial oxidants can induce phosphorylation of vascular
endothelial growth factor receptor 2 (VEGFR2), resulting in
activation of the receptor and subsequent angiogenesis. Similar
to those findings, our previous reports showed that i) IL-35
inhibits lipopolysaccharide (LPS) and proatherogenic lipids LPC
induced HAEC activation (5, 7); ii) IL-35 suppresses vascular
inflammation and atherosclerosis via inhibiting mitochondrial
ROS(8, 9, 34–37); iii) hypoxia may induce thrombus leukocyte
transdifferentiation by upregulating endothelial cell-specific
angiogenic markers (38); and iv) inhibition of caspase-1/
inflammasome activation in EC improves ischemia-triggered
angiogenesis (39, 40). However, the question remained whether
IL-35 modulates ischemia-triggered angiogenesis potentially via
a ROS-related mechanism.
In this study, we examined a novel hypothesis that IL-35
modulates ischemia-induced angiogenesis through activating
integrins and regulating ECM macromolecules. We further
hypothesized that IL-35 may dysregulate the core complex of
EC-specific adhesion junction (AJ, cell–cell adhesion), which is
composed of vascular endothelial cadherin (VE-cadherin), p120-
catenin, b-catenin or plakoglobin (also known as g-catenin), and
a-catenin (actin-binding protein). This cadherin-based AJ
regulates the intracellular actin-myosin network and is essential
for vascular integrity (41, 42). In our study, we used both gain-of-
function (IL-35 recombinant protein injection) and loss-of-
function (Il12rb2−/−) mouse models to examine the role of IL-
35 in ischemia/hypoxia-induced angiogenesis. Protein array and
transcriptome analysis were used to explore the underlying
molecular mechanisms. Our results have demonstrated for the
first time that IL-35 induces ECM remodeling proteins, which
leads to the delayed ECmigration and tube formation in vitro, and
the early phase of HLI-induced angiogenesis in vivo but spare
regenerative angiogenesis at late phase. These findings provide a
novel insight on the future therapeutic potential of IL-35 in




Recombinant human vascular endothelial growth factor
VEGF165 (PeproTech, #100-20), and basic fibroblast growth
factor (FGF2) (PeproTech, #100-18B) were reconstituted in 0.1%
bovine serum albumin (BSA)/phosphate-buffered saline (PBS).
Recombinant mouse IL-35 Fc chimera (Adipogen, #CHI-MF-
11135-C025) was reconstituted in sterile PBS. Recombinant
human IL-35 Fc chimera (Enzo, #ALX-522-140-C010) was
reconstituted in sterile water. Antibodies used against human
in western blot: anti-hypoxia-inducible factor-1a (HIF-1a) (BD,
#610958), anti-PEDF (Santa Cruz BioTechnology, #sc-390172),
anti-b-Actin antibody (Sigma #A5441). Antibodies against
mouse used in flow cytometry: anti-CD45.1 APC-Cy7
(BioLegend, #110716), anti-CD45 allophycocyanin-cyanine
dye 7 (APC-Cy7) (BioLegend, #103116), anti-CD45.2
R-phycoerythrin-Cy7 (PE-Cy7) (eBioscience, #25-0454-82),
anti-CD11b BV421 (BD, #562605), anti-CD31 Brilliant™
Violet 605 (BV605) (BioLegend, #102427), anti-CD31 PE-Cy7,
anti-CD144 APC (Thermo Fisher, #17-1441-80). Viability dyes
used in flow cytometry: live/dead fixable aqua (ThermoFisher,
#L34965), 7-aminoactinomycin D (7-AAD) viability solution
(eBioscience, #00-6993-50). Antibodies against mouse used in
immunofluorescent staining: anti-CD31 (Abcam, #ab28364),
anti-CD45 (BioLegend, #103101), anti-vascular endothelial
(VE)-cadherin (R&D, #AF1002-SP), anti-NG2 NG2 chondroitin
sulfate proteoglycan (Millipore, #ab5320).
Cell Lines and Cell Culture
Human cardiac microvascular endothelial cells (HMVECs, Lonza,
#CC-7030) were cultured in microvascular endothelial cell growth
medium-2 (EGM-2 MV) (Lonza, #CC-3202). Human umbilical
vein endothelial cells (HUVECs) were cultured in M199 medium
(HyClone) supplemented with 20% fetal bovine serum (FBS;
HyClone), endothelial cell growth supplement (ECGS, 50 mg/ml,
BD Biosciences), heparin (50 mg/ml) and 1% penicillin,
streptomycin, and amphotericin (PSA, Invitrogen). Cells were
grown on 0.2% gelatin-coated flasks, plates, or dishes in a
humidified incubator at 37°C with 5% CO2. All in vitro assays
used HMVEC (purchased at P4, used at P8-9), which was justified
to be more pathophysiological relevant angiogenic cell type
compared to HUVEC. In 3D sprouting assay, where HMVEC
had lower efficiencies in bead-coating than HUVEC, earlier
passages of endothelial cell were required for the sprouting
phenotype; here HUVECs at P5 were used.
Fluorescence-Activated Cell Sorting and
RNA Isolation for RNA-Seq
To obtain CD45−CD31+ and CD45+CD31+ cells from mouse
hindlimb, skeletal muscle was dissociated into single-cell
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suspension through the method reported previously (43). Briefly,
hindlimb muscle was dissected, minced, and incubated in muscle
dissociation buffer containing collagenase, type 2 (Worthington,
#LS004176) and dispase II (Life Technologies, #17105-041) for
1.5 h. After washing with FACS buffer (2% FBS in PBS), cells
were stained with surface antibody anti-CD45 (BioLegend,
#103116) and anti-CD31 (BioLegend, #102427) for 30 min at
room temperature. All cell-sorting experiments were performed
using an Aria Cell Sorter (BD Biosciences) in Temple University
Lewis Katz School of Medicine Flow Cytometry Core. The
CD45−CD31+ and CD45+CD31+ cells were sorted directly into
TRIzol, and RNA was extracted using miRNeasy Mini
kit (Qiagen).
Total RNA libraries were prepared by using Pico Input
SMARTer Stranded Total RNA-Seq Kit (Takara). In short, 250
pg–10 ng total RNA from each sample was reverse-transcribed
via random priming and reverse transcriptase. Full-length cDNA
was obtained with SMART (Switching Mechanism At 5′ end of
RNA Template) technology. The template-switching reaction
keeps the strand orientation of the RNA. The ribosomal cDNA is
hybridized to mammalian-specific R-Probes and then cleaved by
ZapR. Libraries containing Illumina adapter with TruSeq HT
indexes were subsequently pooled and loaded to the Hiseq 2500.
Single end reads at 75 bp with 30 million reads per sample were
generated for bioinformatic analysis. RNA-seq data was
deposited into NCBI-GEO dataset (GSE155012).
Protein Extraction and Western
Blot Analysis
Protein extracts were collected from HMVECs or mouse
hindlimb skeletal muscle. Protein concentration was
determined by bicinchoninic acid (BCA) assay with BSA
standards. Protein was separated on SDS-polyacrylamide gel
and transferred onto nitrocellulose membranes. Membranes
were blocked with 5% BSA in Tris-buffered saline containing
0.1% Tween 20 [TBST, 50 mM Tris (pH 7.5), 150mM NaCl, and
0.1% Tween 20 (v/v)]. Membranes were incubated with primary
antibodies overnight at 4°C, then washed extensively with TBST
and incubated with the appropriate horseradish peroxidase-
labeled secondary antibodies for 1 h at room temperature.
Afterwards, membranes were incubated with enhanced
chemiluminescence (ECL) substrate for horseradish peroxidase
(Thermo Scientific, #34578) and the ECL intensity was detected
by Fujifilm LAS-4000. The expression levels of proteins as
indicated by the ECL intensity were measured with ImageJ
software. The experiments with human angiogenesis protein
array (R&D Systems, #ARY007) were performed following the
manufacturer’s protocol.
Enzyme-Linked Immunosorbent Assay
After euthanizing mice, plasma and skeletal muscle were collected
for protein extraction. Less than 50 mg of muscle was added into
molar with liquid nitrogen and ground into powder. 400–1,000 μl
of lysis buffer (Cloud-Clone, #IS007) was used to extract protein.
After sonication at 40 mA for 10 s intermittently and
centrifugation at 10,000 g for 5 min at 4°C, supernatants were
carefully collected into a new 1.5 ml tube. IL-35 protein expression
in mouse plasma and muscle was measured using ELISA kit
(Biomatik, #EKU05328) by following its product instruction.
RNA Isolation and Real-Time Quantitative
Reverse Transcription PCR
RNA collected from HMVECs was isolated using the miRNeasy
Mini Kit (Qiagen, #217004). RNA from mouse hindlimb skeletal
muscle was isolated using RNeasy Fibrous Tissue Mini Kit
(Qiagen, #74704). The cDNA was synthesized using High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
#4368814), and qRT-PCR was performed with iTaq Universal
SYBR Green Supermix (Bio-Rad). Samples were amplified by
40 cycles of 5 s at 95°C and 30 s at 60°C. Results were calculated
using the DD Ct method relative to the reference control gene
of b-actin.
For PCR array, HMVECs were treated with 10 ng/ml of rhIL-
35 for 6 h, triplicate samples were pooled to collect mRNAs,
which were then converted to cDNA and assayed with the RT²
First Strand Kit (Qiagen, #330401). The pooled mRNAs were
used to screen for 84 EC biology-related gene expression changes
following the direction of the Human Endothelial Cell Biology
PCR Array (Qiagen, #330231). Data were analyzed with the
SABiosciences PCR Array Data Analysis Software.
Human EBI3 (ThermoFisher Scientific, #4331182) and mouse
Il12a (Bio-Rad, #10025636) were detected using commercial kits.
All other primers were designed and purchased from Integrated
DNA Technologies. Primer sequences are listed in Table 1.
Immunofluorescence Staining
To prepare the frozen sections, collected samples were fixed in
2% paraformaldehyde (PFA) overnight at 4°C, incubated in 15%
sucrose in PBS (w/v) for 2 h, and then 30% sucrose overnight at
4°C. Gastrocnemius muscle was cut in the center and embedded
with the cut surface facing down in Tissue-Plus O.C.T
compound (Fisher Scientific, #23-730-571) and snap frozen on
an aluminum block (pre-chilled) in liquid nitrogen. Sections of
10-mm in thickness were cut on Leica CRYOCUT 1800.
For paraffin sections, collected samples were fixed in 4% PFA
overnight at 4°C, then transferred into 70% ethanol before
embedding. Sections of 5-mm thickness were deparaffinized
and treated with a heat-induced antigen retrieval with 1 mM
EDTA-NaOH (pH 8.0) solution.
Slides were blocked in PBS with 3% BSA for 1 h at room
temperature. Primary antibodies were incubated overnight at 4°C
in the blocking buffer. Secondary antibodies were added into
the blocking buffer and incubated for 1 h at room temperature.
Excess antibodies were washed in PBS with 0.5% Tween 20. Slides
were then mounted in VECTASHIELD HardSet Antifade
Mounting Medium with 4′,6-diamidino-2-phenylindole (DAPI,
Vector, #H-1500-10). Stained sections were imaged by a Leica TCS
SP8 confocal microscope using ×10, or ×20 objectives.
Tube Formation Assay
Reduced growth factor basement membrane matrix (Trevigen,
#3433-005-R1) was coated on the 15-well μ-slides (ibidi, #81506)
for 30 min. HMVECs were trypsinized, seeded on the coated
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μ-slides at a density of 10,000 cells/ml in EGM-2 MV medium with
or without LPC (30 μM), and incubated for 4–6 h at 37°C. Phase
contrast images were taken at ×6.4 magnification with or without
Calcein AM (Trevigen, #4892-010-01), a viability fluorescent
dye. Images were analyzed using Angiogenesis Analyzer for
ImageJ developed by Dr. Gilles Carpentier (http://image.bio.
methods.free.fr/ImageJ/?Angiogenesis-Analyzer-for-ImageJ).
Wound Healing Migration Assay
HMVECs were seeded on 6-well tissue culture plate and cultured
until 80% confluence. After starvation overnight in EBM2 plus
0.1% FBS, the monolayer of cells were scratched with 1 ml pipette
tip to create an across at the center of the well. Then cells were
gently washed twice with medium to remove the detached cells
and replenished with fresh starvation medium containing FGF2
(80 ng/ml), with or without IL-35 (40 ng/ml). The wound healing
process was monitored for approximately 12 h. Olympus
microscopy IX71 was used to image the cells at the first time
point T0 and the last time point T12. For data analysis, ImageJ
was used to measure the wound area at T0 and T12. Migration
distance = [Area(T0) − Area(T12)]/(2 × Length of the field).
3D Sprouting Assay
Passage (P) 5 HUVECs were trypsinized and incubated with
sterile Cytodex 3 microcarrier beads (GE Healthcare, #17-0485-
01) at the ratio of 500 cells per bead in a sterile tube with EGM-2
medium at 37°C for 4 h. During the 4 h, the mix was gently
shaken every 20 min. Then, around 250 coated beads were
seeded in 0.5 ml fibrin gel (2 mg/ml fibrinogen (Sigma, #F-
8630), 0.15 U/ml aprotinin (Sigma, #A-1153), and 0.625 U/ml
thrombin (Sigma, #T-4648), 100 ng/ml rhVEGF-A165
(Peprotech, #100-20), 30 ng/ml rhFGF-basic (Peprotech, #100-
18B), with or without 30 μM LPC (Avanti, #855675P) in a 24-
well plate. After seeding the beads, 1 ml EGM-2 with 20,000
fibroblasts was added dropwise. Culture medium was changed
every other day, and beads sprouts were counted at day 10.
Animals
All mice used were on a C57BL/6 background. Except
Supplementary Figure 2, in all the other animal experiments,
male mice were used. Apolipoprotein E deficient (ApoE−/−)
mice (strain name: B6.129P2-Apoetm1Unc/J), Il12rb2−/− mice
(strain name: B6.129S1-Il12rb2tm1Jm/J) and wild type (WT)
mice (strain name: C57BL/6J) were purchased from the Jackson
Laboratory (Bar Harbor, ME). All mice were weaned at 3 weeks
of age and maintained on chow diet. In the Matrigel plug assay
experiment, severe combined immunodeficiency (SCID)
(NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) male mice at 12-week
old were used and the experiment was performed with
collaborator Dr. Shu Meng from Houston Methodist Hospital;
female mice did not response to angiogenic stimuli very well,
thus not ideal for this experiment model. In bone marrow
transplantation experiment, CD45.1 WT (strain name: B6.SJL-
Ptprca Pepcb/BoyJ) mice were used as the recipient and
enhanced green fluorescent protein (EGFP) (strain name:
C57BL/6-Tg (CAG-EGFP)131Osb/LeySopJ) male mice were
used as the donor. In cytokine injection therapy experiment,
both male and female mice were used. All animal experiments
were performed in accordance with the Institutional Animal
Care and Use Committee (IACUC) Guidelines and
Authorization for the use of Laboratory Animals and were
approved by the IACUC of Temple University Lewis Katz
School of Medicine and Houston Methodist Hospital.
Mouse Genotype
Mouse genotypes were confirmed with PCR followed by agarose
gel separation. Extracta DNA Prep for PCR (Quanta, #95091)
was used to extract DNA from mouse toe. Briefly, mouse tissue
was digested with 50 ml of extraction reagent at 98°C for 30 min,
and then added 50 μl of stabilization buffer and stored at 4°C.
IL-12RB2 genes were amplified with primers for the mutant
gene (5′-CACGGGTAGCCAACGCTATGTC-3′ and 5′-GCCC
TGAATGAACTGCAGGCG-3′) and the WT gene (5′-GTGTG
CAAGCTTGGCACTGTGACCGTCCAG-3′ and 5′-GTTT
AGCTTGCAG ACAAACAAGGTCATACC-3′). The PCR
cycle for IL-12RB2 was 94°C for 3 min, 35 cycles of 94°C for
30 s, 72°C for 1 min, 66.8°C for 1 min, and 72°C for 2 min.
ApoE genes were amplified with 3 primers (5′-GCCTAGCC
GAGGGAGAGC CG-3′ , 5′-TGTGACTTGGGAGCTCT
GCAGC-3′, and 5′-GCCGCCCCGACTGCATCT-3′). And the
TABLE 1 | Sequences of human and mouse primer pairs.
Species Gene Name Forward (from 5′ to 3′) Reverse (from 5′ to 3′)
Human ACTB ACCTTCTACAATGAGCTGCG CCTGGATAGCAACGTACATGG
Human IL12A CTCCAGACCCAGGAATGTTC ATCTCTTCAGAAGTGCAAGGG
Human IL6ST GCAACATTCTTACATTCGGACAG TCCCACTCACACCTCATTTTC
Human IL12RB2 ATCTCCCTTTCTGTTTTCCCC TGAGGGCACACTGACTTTAAG
Mouse Actin GGCTGTATTCCCCTCCATCG CCAGTTGGTAACAATGCCATGT
Mouse Ebi3 CAAGGAACAGAGCCACAGAG GGGATACCGAGAAGCATGG
Mouse Il6st AGATGAAGGTGGGAAAGATGG GTTAAAGCAGAACAAGACGCC
Mouse Il12rb2 GAACGCCTTTTCATTTCCTGG TGGATGTGAGTTTTGAGAGCG
Mouse Col1a2 AAGGATACAGTGGATTGCAGG TCTACCATCTTTGCCAACGG
Mouse Col11a1 ACAAAACCCCTCGATAGAAGTGA CTCAGGTGCATACTCATCAATGT
Mouse Col18a1 CAGACCCTGACAAGTTCCAG AGCCACTTCCAAAATCTCCAG
Mouse Adam12 ACAAGTCCAACCTCACCATG TTCCTTGCCTCTGAAACTCTC
Mouse Mmp12 CTGCTCCCATGAATGACAGTG AGTTGCTTCTAGCCCAAAGAAC
Mouse Mmp14 GGATGGACACAGAGAACTTCG TTTTGGGCTTATCTGGGACAG
Mouse Mmp19 GAGCCCAGAGACAAGAGATG AAGCATAAGTCTTCCCACGAG
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PCR cycle for ApoE was 3 cycles of 94°C for 5 min, 60°C for 30 s,
72°C for 30 s, and 30 cycles of 94°C for 30 s, 60°C for 30 s, 30°C
for 20 s, and 72°C for 7 min.
The PCR product was then mixed with DNA loading dye and
separated by gel electrophoresis with a 1.5% agarose gel. The
DNA sizes for IL-12RB2 are 265 bp (WT) and 500 bp (mutant),
and that of ApoE are 155 bp (WT) and 245 bp (mutant).
Hindlimb Ischemia Model
Age-matched 10–12-week-old male or female mice were used in
HLI model as reported previously (44). Under anesthesia, an
incision was made in the skin at the mid-portion of the left
hindlimb. The femoral artery was then dissected free from the
nerves and the proximal and distal loci of the femoral artery were
ligated and cut, as well as its side branches. Hindlimb blood flow
was measured on postoperative days 0, 3, 7, 14, 21, and 28 using a
laser Doppler imaging (LDI) blood flow analyzer (moorLDI2-IR,
Moor Instrument). The penetration depth is ~5 mm when the
Infra-Red laser of 785 nm is used (45). Blood flow was
quantitatively assessed by the ratio of mean flow signals of the
left (ischemic) to the right (non-ischemic) plantar. Mice with
blood flow ratio higher than 0.2 at postoperative day 0 were
excluded to ensure the success of the ligation procedure, which
were correlated well with that reported (46). 80–90% blood loss is
typical of what we see after a femoral artery ligation procedure,
which is also consistent with the application note on HLI by
Moor Instrument. Calf muscles including gastrocnemius and
soleus were used for most molecular experiments except flow
cytometry. Due to the limited alive cell after single cell
suspension, the whole limb muscle was dissected for
flow cytometry.
Matrigel Plug Assay
Matrigel (Corning, #354234) was thawed at 4°C overnight before
the experiment. SCID male mice were anesthetized and injected
with Matrigel subcutaneously in the shaved abdomen region of
the mice (two injections in each mouse). Each Matrigel injection
contains 400 μl total volume (300 μl Matrigel + 100 μl other
reagents with the final concentrations of 30 U/ml of heparin, 40
ng/ml of FGF2, and with or without 40 ng/ml of IL-35). Matrigel
plugs were removed after 5 days for molecular studies.
Cytokine Injection
Recombinant mouse IL-35 was administered intramuscularly
(i.m.) (0.3 μg/gastrocnemius (GC) muscle in 20 μl PBS) at the
time of HLI procedure, and three times a week afterwards until
the end of observation. The non-surgery limb and PBS control
group limb were injected with 20 μl PBS as the internal and
experimental control, respectively. The used dose was based on
similar literatures using cytokine injection in mouse muscle (47).
Bone Marrow Transplantation
CD45.1 WT male mice at 5-week old were irradiated with a
single dose of 8 min and 29 s in RS2000 X-ray irradiator from
Radsource. Then, bone marrow cells were collected from EGFP
donor mouse femurs and filtered through a 70 mM cell strainer.
Each irradiated CD45.1 mouse was injected by retro-orbital with
5 × 106 donor bone marrow cells. To assess the irradiation
efficacy, control mice were irradiated but did not receive donor
bone marrow cells. After 6 weeks, all recipient mice survived,
while the control mice were dead. Peripheral blood was assessed
with flow cytometry, and more than 90% of mononuclear cells
were EGFP+. The chimeric mice were then performed with HLI
surgery and followed with IL-35 or PBS injection.
Statistical Methods
Data were expressed as the mean ± standard error of the mean
(SEM) throughout the manuscript. For comparisons between
two groups, the two-tailed Student t-test was used for evaluation.
For comparisons across multiple groups, one-way ANOVA with
Bonferroni post-test adjustment was used. For the blood
perfusion ratio, since the longitudinal data were collected over
a 4-week period on mice for the various experimental groups
[e.g., 2 strains (WT vs. Il12rb2) × 2 treatments (PBS or IL35)] on
both sexes, we employed the mixed-effects linear model
approach to explore several potential effects of interest,
including the gene effect, treatment effect, sex effect, and time
effect. Estimation and testing of such effects between various groups
of interest were performed using the least squares means method
with the Tukey–Kramer adjustments made for multiple
comparisons in the mixed-effects regression models while taking
into account of the fact that multiple data points were collected on
each mouse over time. Variability of the blood perfusion ratio as
well as its correlation across different days were allowed to vary by
the combinations of time points and groups that were being
examined, which is a far better model than that being afforded
by a common ANOVA model. Interaction between time and
various factors of interest (e.g., strain, treatment, and sex) was
always considered in the regression model. Data shown are
representative of two to three independent experiments, including
analysis from wound healing assay, immunofluorescent staining,
flow cytometry, and western blot. *, p < 0.05; **, p < 0.01; ***, p <
0.001; ****, p < 0.0001.
RESULTS
IL-35 and Its Receptor Subunit IL-12RB2,
but Not IL-6ST, Are Induced in the
Ischemic Muscle After Hind Limb Ischemia
Previous reports showed that a special population of Treg
potentiates muscle repair (48); and IL-35 is predominantly
secreted by Treg (3, 13), suggesting a possibility that IL-35
may modulate hind-limb ischemia (HLI) angiogenesis related
to muscle repair. We hypothesized that IL-35 signaling is
induced in HLI angiogenesis model (Figure 1A). At
physiological conditions, the gene expressions of IL-35
subunits (IL-12A and EBI3) are very low in the skeletal
muscle, and protein levels are undetectable based on the
Human Protein Atlas database (http://www.proteinatlas.org),
which correlated well with our previous report (4). IL-35
signaling involved three possible formats further described in
the following results (Figure 1B). To test this hypothesis, we
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extracted RNAs from ischemic muscle at 0, 3, and 7 days post-
ischemia (dpi). The results showed significantly increased
expression of IL-35 subunit EBI3 and IL-35R subunit IL-
12RB2, but reductions of IL-35 subunit IL-12A and IL-35R
subunit IL-6ST (Figure 1C). The upregulation of EBI3 and
downregulation of IL-12A were consistent with the results of
the microarray dataset GSE3313 found in NIH Geo DataSets
database (https://www.ncbi.nlm.nih.gov/gds/) (Supplementary
Figure 1A), where gene expression data were also collected
from the ischemic mouse muscle after HLI (49). Because IL-35
subunits are shared with other IL-12 family cytokines and the
inconsistent changes of the two subunits induced by ischemia, we
performed ELISA to detect the changes of IL-35 protein levels in
wild-type (WT) mouse plasma and ischemic muscle after HLI.
The results showed that IL-35 was induced in ischemic muscle
after HLI and peaked at 7 dpi, which was about threefold higher
compared to the basal level in non-surgery mouse muscle
(Figure 1D). However, its expression level was not detectable
in plasma at the basal level or after HLI (Figure 1E).
To mimic the ischemic environment in vivo, human
microvascular endothelial cells (HMVECs) were cultured
under 0.2% O2, where hypoxia-inducible factor 1 (HIF1A) was
significantly upregulated (Supplementary Figure 1B). HIF1A
upregulation indicated the successful establishment of hypoxic
environment. The results showed that 24-h treatment of hypoxia
induced the gene expressions of IL-35 cytokine subunits IL-12A
and EBI3, decreased that of IL-6ST, while did not change that of
IL-12RB2 in HMVECs (Supplementary Figure 1C). These
results suggested that the induction of IL-35 cytokine and its
receptor signaling in ischemic muscle the first 12 days after HLI
and hypoxic HMVEC was of pathophysiological relevance, and
IL-12RB2 was the more responsive IL-35 receptor (IL-35R)
subunit than the second IL-35R subunit IL-6ST. These results
suggest that IL-12RB2-IL12RB2 homodimer may be responsible
for IL-35 signaling in ischemia muscle.
Hindlimb Ischemia-Induced Angiogenesis
Is Improved in IL12RB2−/− Mice, in ApoE
−/−/IL12RB2−/− Mice Compared to Wild-
Type Controls, and ApoE−/− Controls,
Respectively, Where Hyperlipidemia
Inhibits Angiogenesis In Vivo and In Vitro
IL-35 receptor has a few functional formats (Figure 1B), which
include: 1) homodimer of IL-12RB2, 2) homodimer of IL-6ST, 3)
heterodimer of IL-12RB2 and IL-6ST, and 4) heterodimer of IL-
12RB2, and IL-27RA (13, 14, 50). Previously we reported that IL-
35 signal is abolished by either IL-12RB2 or IL-6ST inhibition in
ECs (5). In our study, the induction of gene expression of IL-
12RB2 and reduction of IL-6ST in the ischemic muscle (Figure
1C) suggested that IL-12RB2, potential homodimer, played an
important role in regulating IL-35 signaling in HLI model. As we
recently reviewed (13), IL-12RB2 is the receptor subunit shared
by two IL-12 family cytokines, IL-12 (pro-inflammatory) and IL-
35 (anti-inflammatory), while IL-6ST as a receptor subunit is
widely shared by IL-6 family cytokines, which predominantly
drive pro-inflammatory responses. Also, it has been shown that
IL-12RB2 deficiency leads to spontaneous autoimmunity in aged
mice (51), which indicates that IL-12RB2 is the anti-




FIGURE 1 | IL-35 and its receptor subunit IL-12RB2, but not IL-6ST, are induced in the ischemic muscle after hindlimb ischemia (HLI). Calf muscle including
gastrocnemius and soleus was used in (C, D). (A) Schematics of HLI surgery and the time points of tissue collection. (B) Schematics of IL-35 signaling complex.
(C) Normalized gene expression of IL-35 signaling complex in ischemic muscle at pre-ischemia (control), 3 and 7 days post-ischemia (dpi). (D, E) IL-35 protein level
in skeletal muscle and mouse plasma at indicated dpi. All animal results were collected from male mice. Data are presented as mean ± SEM. ND, not determined;
*p < 0.05; **p < 0.01; ****p < 0.0001.
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function of IL-35 (14, 52). We hypothesized that IL12RB2
mediates IL-35 inhibition of HLI-triggered angiogenesis. To
examine this hypothesis, we performed HLI procedure on IL-
12RB2 deficient mice. The result showed for the first time that
IL-12RB2−/− mice have significantly improved blood
reperfusion in the ischemic legs compared to those of WT
control mice (Figure 2A), suggesting that IL-35 inhibits HLI-
induced angiogenesis via IL-12RB2-dependent manner.
One disadvantage of the HLI mouse model to study







FIGURE 2 | Hindlimb ischemia (HLI)-induced angiogenesis is improved in Il12rb2−/− mice, compared to WT, and in ApoE−/−/Il12rb2−/− mice compared to
ApoE−/−, where hyperlipidemia inhibits angiogenesis in vivo and in vitro. (A) Blood perfusion ratio of Il12rb−/− and WT mice in HLI model. Hindlimb blood flow was
measured on day post-ischemia (dpi) 0, 3, 7, 14, 21, and 28 with the plantar looking up using a laser Doppler blood flow analyzer. Blood flow was quantitatively
assessed by the ratio of mean flow signals of the ischemic to the non-ischemic plantar in black rectangular area. (B) Blood perfusion ratio of ApoE−/−/Il12rb2−/−,
ApoE−/−, and WT mice in HLI model. (C) Experimental schematics and representative images of human microvascular endothelial cell (HMVEC) tube formation. Cells
were seeded on Matrigel for 4 h with or without 30 µM of LPC treatment. (D) Total master segment length was measured with an ImageJ package of Angiogenesis
Analyzer. (E) Experimental schematics and representative images of 3D sprouting assay. Human umbilical vein endothelial cell (HUVEC)-coated beads were
embedded in fibrin gel for 10 days with or without 30 µM of LPC treatment. (F) Statistics of longest sprout length. (G) Statistics of sprouts per bead. Sprouts per
bead and longest sprout length were manually measured blinded to the treatment. Scale bars are 200 µm in (C, E). All animal results were collected from male mice.
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ****p < 0.0001; #P < 0.05.
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is not comparable to aging diseases like PAD (53). Hyperlipidemia
is a common complication in patients with PAD. We (Figure 2B)
and others (54) have seen that hyperlipidemia dampens
angiogenesis in vivo. We previously reported that gene
expressions of IL-35 subunits and its essential receptor subunit
IL-12RB2 were induced in mouse aorta after 3-week high-fat diet
in ApoE−/− mice (9), the impaired angiogenesis may partially act
through the induction of IL-35. We hypothesized that IL-35
inhibits HLI-triggered angiogenesis in the presence of
hyperlipidemia. Thus, to be more clinically relevant, we
also used hyperlipidemia model by crossing Il12rb2−/− mice
with hyperlipidemia-conditioned apolipoprotein E deficient
(ApoE−/−) mice. Consistently, ApoE−/−/Il12rb2−/− showed
significant improvement of blood reperfusion in the ischemic leg
at 7 dpi; however, the overall rescue effect of IL-12RB2 deficiency
at other time points was not significant (Figure 2B). Of note,
the kinetics of the response to HLI in C57 wild-type mice and
ApoE−/− mice appeared different, suggesting that hyperlipidemia
stimuli inhibit angiogenesis. To verify the effect of hyperlipidemia,
two in vitro angiogenesis models including EC tube formation
assay and three dimensional (3D) sprouting assay showed that 30
μM lysophosphatidylcholine (34) (LPC, a proatherogenic lipid
that mimics hyperlipidemia stimuli on EC in vivo) restrained
tubular network formation in HMVECs (Figures 2C, D) and the
sprouting length from the 3D beads (Figures 2E, F), but not the
number of sprouts per bead in HUVECs (Figure 2G). The reason
that early passage of HUVEC was used in 3D sprouting assay was
because HMVEC do not attach to 3D beads well nor sprout well.
Our results were also well correlated with that reported by Dr.
Belmadani on IL35 cytokine subunit p35 knockout mice fed with
chow diet and high fat diet in 14 dpi (55). Of note, as we reviewed
recently, IL35 cytokine subunit p35 is shared with IL12 (13).
Taken together, these results suggest that IL-35 inhibits HLI-
induced angiogenesis in the day 7 after HLI in the presence
of hyperlipidemia.
IL-35 Cytokine Injection Delays Blood
Perfusion Recovery at Day 14 After
Hindlimb Ischemia and Increases Gene
Expression of IL-12RB2
As we discussed earlier, IL-12RB2 is the receptor subunit shared
by two IL-12 family cytokines, IL-12 and IL-35. Of note, IL-12
has been shown as an anti-angiogenic factor in both tumor (56)
and myocardial infarction (57). Thus, we thought that the
improvement of angiogenesis in HLI by deleting IL-12RB2
could be merely the effect of blocking IL-12 signaling rather
than IL-35. To rule out the possible effect of IL-12 in HLI, we
hypothesized that IL-35 cytokine injection inhibits HLI-triggered
angiogenesis as the gain-of-function approach. To examine this
hypothesis, we use IL-35 injection of recombinant mouse IL-35
protein directly into ischemic muscle after HLI with the method
that we reported previously (9). As shown in Figure 3A, mice
were administered via i.m. with IL-35 [0.3 μg/gastrocnemius
(GC) muscle in 20 μl PBS] at the time of HLI procedure (47, 58,
59) and three times a week afterward until the end of the
observation as we previous reported (60). The results showed
that IL-35 injection inhibited blood reperfusion compared to the
PBS group, especially at 14 dpi (Figure 3B). And this effect of IL-
35 at least partially relied on receptor subunit IL-12RB2
(Supplementary Figure 2A), where IL-12RB2 deficiency
rescued the dampened blood flow recovery by IL-35. We also
found that IL-35-IL12RB2 signaling inhibited HLI-induced
angiogenesis specially in male mice, and male outperforms
female regardless of the treatment or genotype (Supplementary
Figures 2B–F), which were consistent with previous report (61).
Sex differences in vascular physiology and pathophysiology have
been well accepted and should be put into consideration for the
future studies.
Then, since bone marrow transplantation allows for
determining the roles of bone marrow-derived cells versus
tissue resident cells in modulating HLI and other vascular
pathologies as we reported (62), we hypothesized that bone
marrow (BM) cells promote HLI-triggered angiogenesis. To test
this hypothesis, we performed BM transplantation with enhanced
green fluorescence protein (EGFP)-transgenic mouse BM (BM
transplantation method, Figure 3C). The results showed that IL-
35-injected mouse GC muscle after HLI had much bigger
avascular areas than that of the controls, judged by significant
less CD31+ staining and surrounding EGFP+ BM-derived cells at
14 dpi (Figures 3D, E). However, we did not see significant
changes of vascular density at the vascular area, judged by the
percentage of CD31+ area in the field of view of IL-35-treated HLI
mice (Figure 3F), suggesting that IL-35 inhibitory effects was
focused on HLI-triggered angiogenesis. In addition, the EGFP+
BM-derived cells were in high concentration in vascular areas but
not in avascular areas, suggesting that EGFP+ BM-derived cells
facilitate angiogenesis in the presence of IL-35. Of note, we did
not find the evidence that GFP+ BM-derived cells incorporate
into CD31+ cells (not shown). This result was confirmed by
another experiment with muscle samples analyzed by flow
cytometry and immunofluorescent (IF) staining (Figures 3G,
H), though there was a trend of decreasing EC percentage at the
earlier time point (3 dpi) of HLI in the IL-35-injected group. To
confirm the inhibitory role of IL-35 in angiogenesis, we
performed another in vivo angiogenesis model, Matrigel plug
assay, where IL-35-contained plugs showed significantly less
growth of new blood vessel (Supplementary Figure 3). These
results suggest that IL-35 inhibits HLI-triggered angiogenesis in
the HLI-affected area of tissue but not in the HLI-non-affected
areas of tissue.
We also found that IL-35 injection upregulated gene
expression of IL-12RB2 but not IL-6ST in the ischemic muscle
at 3 dpi (Figure 3I). The above qRT-PCR assay was performed
using the whole muscle extracts, which included many cell types
such as immune cells, vascular smooth muscle cells (VSMCs),
and ECs. The induction of both IL-35 subunits, IL-12A and
EBI3, implicated that exogenous IL-35 could stimulate these
immune cells (14, 50) and/or ECs in the ischemic muscle to
secrete more IL-35. In our previous findings, IL-35 can directly
signal through EC and inhibit LPC- or LPS-induced EC
activation (5, 8). Therefore, we treated HMVEC with IL-35 for
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FIGURE 3 | IL-35 cytokine injection delays blood perfusion recovery in the ischemic leg of hindlimb ischemia (HLI) and increases gene expression of IL-12RB2.
(A) Experimental schematics. IL-35 group mice were intramuscularly (i.m.) administered with IL-35 [0.3 µg/gastrocnemius (GC) muscle in 20 µl PBS] at the time of
HLI procedure and three times a week afterwards until the end of observation. The non-surgical limb was also injected with 20 µl PBS as internal control. (B) Blood
perfusion ratio of IL-35- or PBS-injected WT or Il12rb2−/− mice. (C) Bone marrow transplantation experimental schematics. (D) Representative images of the whole
GC muscle (left panel) and higher magnification of vascular density (right panel) in vascular area of PBS- or IL-35-injected ischemic muscle at 14 dpi. Tissues were
stained with anti-CD31 (red) and DAPI. Lines, where blood vessels were rarely visible. The left two images were taken using tile scan in Leica TCS SP8 system and
merged to present the whole tissue section. The avascular area was indicated with red dash at 14 dpi. (E) Statistics of the percentage of the avascular area EGFP+
indicated infiltrated bone marrow-derived cells. (F) Statistics of the percentage of CD31+ cells in the vascular area of the GC muscle at 14 dpi. (G) Statistics of
percentage of CD31+ cells in CD45− cell population in IL-35 or PBS-injected groups using flow cytometry. (H) Percentage of CD45+CD31+ ECs in IL-35 or PBS
injected ischemic muscle at 3 and 14 dpi using immunofluorescent staining. (I) Normalized gene expression of IL-35 signaling complex in the ischemic muscle at 3
dpi. IL-35 group mice were i.m. injected with IL-35 at the time of HLI surgery. (J) Normalized mRNA expression levels of IL-35 receptor subunits after 6 h of 40 ng/
ml of IL-35 treatment in HMVECs under normoxia or hypoxia condition. All animal results were collected from male mice. Data are presented as mean ± SEM. *p <
0.05; **p < 0.01; ****p < 0.0001.
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6 h under normoxia or hypoxia to examine the direct effect on
EC. Consistently, the result showed that gene expression of IL-
12RB2, but not IL-6ST, was induced in normoxia, though not in
hypoxia (Figure 3J).
IL-35 Spares Regenerative Angiogenesis
at the Late Phase of Hindlimb
Ischemia Recovery
Our previous report showed that inhibition of HLI-activated
danger associated molecular pattern receptors (DAMP-Rs)
caspase-1/inflammasome activation in EC improves angiogenesis
at 1 dpi, 3 dpi, and 7 dpi but not at the late phase in 10 dpi and 21
dpi (39), suggesting that after 7 dpi, pro-inflammatory
mechanisms are decreased and anti-inflammatory mechanisms
play more significant roles than pro-inflammatory mechanisms.
We found that IL-35 did not significantly inhibit the regenerative
angiogenesis in the late phase of hindlimb ischemia-triggered
angiogenesis in 21 and 28 dpi (Figure 3B), which were well
correlated with our other two results that first, IL35 cytokine levels
were increased at 1, 7, and 14 dpi and were peaked at 7 dpi
(Figure 1D); second, the deficiency of IL12RB2 in ApoE−/−
background did not significantly improve angiogenesis at 21
and 28 dpi (Figure 2B); on those two time points the blood
perfusion in the deficiency of IL-12RB2 had no differences with
that of ApoE−/− single gene knockout controls. Of note, one of the
discrepancies was that IL12RB2−/− mice have significantly
improved blood reperfusion in the ischemic legs at all the time
points compared to those of WT control mice (Figure 2A), which
may result from the fact that IL-12RB2 is the receptor subunit
shared by two IL-12 family cytokines, IL-12 and IL-35; and IL-12
may inhibit regenerative angiogenesis. A previous report showed
that at 21 dpi, HLI-induced muscle injury is almost fully recovered
as judged by the expressions of 18 chemokines and receptors, 23
cytokines and receptors, 26 energy metabolism regulators and
histological recovery of muscles (63). The findings suggested that
starting from 14 dpi, HLI-triggered muscle injury experiences
regenerative angiogenesis and muscle repair, which continues
to 28 dpi. Therefore, taken together, our new findings suggest
that IL-35 inhibits HLI-triggered inflammatory angiogenesis at the
early phase and spare regenerative angiogenesis at the late phase of
HLI recovery.
Transcriptome Analysis of Endothelial
Cells at 14 Days Post-Ischemia Reveals a
Disturbed Extracellular Matrix Re-
Organization in IL-35-Injected Mice
We hypothesized that IL-35 regulates angiogenesis via
modulating the transcriptome of EC in the muscle after HLI.
To examine this hypothesis, we specifically isolated
CD45−CD31+ bona fide EC from the ischemic muscle (Figure
4A) at 0, and 14 dpi using fluorescence-activated cell sorting
(FACS). About 0.1 million ECs were collected for RNA
extraction and deep-sequencing. A comparison of EC RNA-
Seq data (transcriptome) of IL-35 injection and PBS control was
made at 14 dpi since our data presented above showed that IL-35
inhibits angiogenesis at 14 dpi (Figure 3B). Consistent with the
Laser Doppler result that the blood flow of PBS-injected group
recovered about 80% of that of non-ischemic leg at 14 dpi, we
found this group had a very similar transcriptomic pattern
compared to the control group (without HLI surgery).
However, the IL-35-injected group showed a quite different
gene expression profile. With the significance criteria of false
discovery rate (FDR) <0.05, |fold change (FC)| >1.5 and Max
[fragments per kilobase of exon model per million reads mapped
(FPKM)] >5, there were 341 differentially expressed genes
(DEGs) in IL-35-injected ECs (Figure 4B). Gene set
enrichment analysis (GSEA) (https://www.gsea-msigdb.org/
gsea/index.jsp) revealed several significant enriched gene sets
regulating ECM remodeling, including molecular pathways of
collagen, and integrin b1 and b3 (Figure 4C).
This enrichment gene set profile is likely due to the IL-35-
upregulated genes in the collagen family (eight genes including
types I, V, VI, VIII, XII, XIV, and XVIII), matrix metalloproteinase
(MMP) family (three genes including Mmp12, Mmp14, and
Mmp19), and integrin molecules (three genes including Itgb2,
Itgb3, and Itga11). Representative gene expression changes were
listed in Figure 4D. Due to the limited cell numbers of
CD45−CD31+ endothelial cells sorted from ischemic muscle at 14
dpi, we did qRT-PCR on RNAs collected from whole ischemic
muscles instead to verify the gene expression changes. The tested
genes did show an upregulation trend at 14 dpi, but not at 3 dpi
(Figure 5A). We also saw the increasing trend of collagen
deposition in ischemic gastrocnemius (GC) muscle at 14 dpi
(Figure 5B), which was consistent with the recently reported
observations of IL-35 in myocardial infarction (64). Moreover, to
consolidate the finding, additional collagen gene expressions were
analyzed. The expression changes of eight out of 47 collagen-
related genes (Supplementary Figure 4) were significantly
upregulated in our CD45−CD31+ mouse endothelial cells from
IL-35-treated mice in comparison to that of non-treated control
mice (Figure 4D), which suggests that IL-35 may increase collagen
deposition by upregulating collagen-related gene expression. The
proper angiogenic process in which new blood vessels sprout from
existing ones largely relies on timely regulation of ECM
degradation and synthesis. These over-activated ECM remodeling
genes by IL-35 at 14 dpi of HLI indicated the inhibited angiogenesis
in the early stage and therefore delayed vascular/tissue repair.
IL-35 Downregulates Three Reactive
Oxygen Species (ROS) Promoters and
Upregulates One ROS Attenuator, Which
May Functionally Mediate IL-35
Upregulation of Anti-Angiogenic
Extracellular Matrix Proteins in ECs
Dr. Kevil’s team reported that sodium nitrite significantly
restores ischemic tissue perfusion by 3 dpi, which returned to
normal by 7 dpi (65). In addition, Dr. Belmadani’s team reported
that nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase 4 (Nox4) is significantly increased in ischemic muscle in
HLI (55). These reports demonstrated that ROS and RNS play a
significant role in modulating the pathophysiological processes
of HLI. Recently, we reported that IL-35 inhibits human aortic
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EC activation via suppressing ROS generation (8, 9), mitogen-
activated protein kinase pathway (5), epigenetic (9) and gene
transcription (8). Of note, our experimental data have
demonstrated for the first time that IL-35 not only suppresses
inflammation but also inhibits ROS-mediated processes. To
further demonstrate that ROS play significant roles in
modulating HLI-triggered inflammation and regeneration, we




FIGURE 4 | Transcriptome analysis of endothelial cells (ECs) at 14 days post-ischemia (dpi) reveals a disturbed extracellular matrix (ECM) reorganization in the IL-35-
injected mice. (A) Flow cytometry cell sorting strategy. Hindlimb muscle from control (Ctrl, without surgery) or ischemic mouse (PBS and IL-35 groups) at 14 dpi was
dissected and digested for single cell suspension. Cells were stained with the surface markers of CD31 BV605 and CD45 APC-Cy7 and sorted by Aria Cell Sorter
(BD Biosciences). 1 × 105 cells of ECs from each sample were collected for RNA extraction and deep-sequencing. (B) Heatmap of the differentially expressed genes
(DEGs) in ECs of IL-35- or PBS-injected, and control groups. With the criteria of false discovery rate (FDR) < 0.05, |FC| > 1.5, and max (fragments per kilobase of
transcript per million mapped reads, FPKM) > 5, we got 341 DEGs. The green-red color key was scaled based on the z-score of FPKM within the row. (C) Gene set
enrichment analysis (GSEA) of the gene expression changes of ECs in IL-35-injected mouse compared to that of PBS group. Four of the most enriched pathways
were presented. (D) Representative gene expression changes in different categories of ECM proteins. All results were collected from male mice. n = 3.
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GSEA database in the time course, 1, 7, and 14 dpi by using the
wild-type male mouse microarray datasets GSE3313 in the NIH
GEO database (https://www.ncbi.nlm.nih.gov/gds/) (49). As
shown in Supplementary Figure 5, the expressions of 116 out
of 165 ROS regulators (70.3%) were significantly modulated in
the different time courses after HLI, suggesting that ROS
regulators play significant roles in modulating inflammatory






FIGURE 5 | IL-35 induces extracellular matrix genes in vivo, possibly via impairing the core complex in endothelial cell adhesion junction, (VE-cadherin)–plakoglobin–
(a-catenin). (A) Confirmation of RNA-Seq results by qRT-PCR. Representative genes included collagens and matrix metalloproteinases, which were significantly
upregulated in RNA-Seq data. After IL-35 or PBS injection following HLI for 3 or 14 days (same as Figure 3A), RNA was extracted from the ischemic muscle. n ≥ 3.
(B) Representative images of Masson’s trichrome staining of gastrocnemius (GC) muscle (left panel) and higher magnification (right panel) of non-necrotic areas
(black arrows) showing the collagen deposition. The stars indicated necrotic tissues with dark purple staining. (C) The top five upstream regulators predicted to be
significantly activated or inhibited using IPA core analysis. (D) The network of a-catenin regulating 18 downstream molecules that were significantly changed in IL-35-
treated ECs in the ischemic muscle at 14 days post-ischemia (dpi). (E) Statistics of a-catenin protein level in human microvascular endothelial cells (HMVECs).
(F). The gating strategy of mouse EC from ischemic muscle. Digested muscle cells were first gated for singlet with forward scatter (FSC)-Area and FSC-Height, alive
cells with FSC-Area and LIVE/DEAD (stains only dead cells), non-debris with FSC-Area and side scatter (SSC)-Area, and then CD45− cells with antibodies of CD45.2
PE-Cy7 and CD45.1 APC-Cy7. (C) Density plot with antibodies of CD31 BV605 and VE-cadherin APC. CD31+ ECs were gated from the CD45- cell population.
(G) Statistics of VE-cadherin median fluorescent intensity (MFI) in IL-35 or PBS-injected groups. All animal results were collected from male mice. Scale bar sized are
as indicated in the pictures. Data are presented as mean ± SEM.
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first time, the early phase inflammatory angiogenesis ROS
regulators and the late phase regenerative angiogenesis ROS
regulators. It has been reported that hypoxia triggers reactive
oxygen species (ROS)-mediated inflammatory cell recruitment,
migration and inflammation (66, 67), which may be the
dominant feature in the early phase in HLI. Our previous
report showed that IL-35 inhibits mitochondrial ROS-mediated
HAEC activation and atherosclerosis. In the regenerative phase,
as blood supply restores, hypoxia-triggered inflammation is
decreased. Tissue remodeling and regeneration become the
dominant feature. The mild hypoxia promotes survival and
proliferation even in the absence of mitochondrial form of
manganese superoxide dismutase (SOD2) (68, 69). As we
reviewed recently (13), IL-35 promotes Treg generation, and
Treg facilitates tissue remodeling and regeneration (70). Future
work is needed to characterize the detailed molecular
mechanisms and features of these newly proposed two phases
of HLI. Taken together, our results and analysis suggest that
oxygen tension and ROS (71) within the muscle may orchestrate
the dominant events and transition of the two phases of HLI.
To determine whether ROS inhibition serves as a novel
mechanism underlying IL-35 modulation of angiogenesis, we
hypothesized that IL-35 inhibition of ROS may mediate IL-35
upregulation of anti-angiogenic extracellular matrix proteins
discussed above (Figure 6A). To test this hypothesis, we first
determined whether IL-35 inhibits some ROS-promoting genes
and upregulates ROS-attenuating genes. As shown in Figure 6B,
the expressions of 165 ROS regulator genes in the GSEA database
were examined in the RNA-Seq date of IL-35-treated mouse
CD45−CD31+ ECs in comparison to that of PBS treated mouse
ECs. We found that IL-35 significantly downregulates the
expressions of three ROS promoters including DNA damage
inducible transcript 4 (Ddit4, REDD1, or HIF-1 responsive
RTP801), tumor necrosis factor-a (TNF), and xanthine
dehydrogenase (Xdh, XOR) and upregulates ROS inhibitor
fibulin-5 (Fbln5), which were well correlated with IL-35
suppression of ROS in ECs as we reported (8, 9). We noticed
that IL-35 inhibited ROS promoters DDIT4 and XDH were in
the inflammatory angiogenesis ROS promoter group




FIGURE 6 | IL-35 inhibits the expression of reactive oxygen species (ROS) regulators including downregulation of ROS promoters such as Ddit4, TNF and Xdh and
upregulation of ROS attenuator fibulin-5 (Fbln5), which are connected to downstream extracellular matrix proteins, revealed by Cytoscape analysis. (A) A schematic
presentation of IL-35 inhibition of reactive oxygen species generation and IL-35 upregulation of anti-angiogenic extracellular matrix proteins. Of note, we have two
publications that clearly indicate IL-35 inhibition of ROS generation (the PMIDs included). (B) Our RNA-Seq data analysis indicated that IL-35 downregulates three ROS
promoter genes including DNA damage inducible transcript 4 (Ddit4, REDD1, HIF-1 responsive RTP801), tumor necrosis factor-a (TNF), and xanthine dehydrogenase
(Xdh, XOR) and upregulates ROS inhibitor fibulin-5 (Fbln5) in CD45-CD31+ endothelial cells (EC) treated with IL-35 versus PBS-treated controls with the criteria of false
discovery rate (FDR) < 0.05. The regulatory functions of these four ROS regulators were reported and the PMIDs were included. Of note, the expression of 165 ROS
regulators were examined in the Gene Set Enrichment Analysis (GSEA, https://www.gsea-msigdb.org/gsea/msigdb/cards/GO_REACTIVE_OXYGEN_SPECIES_
METABOLIC_PROCESS). (C) The network data integration database Cytoscape analysis (https://cytoscape.org/) was used to analyze the network connection between
ROS regulators and anti-angiogenic extracellular matrix proteins. The small dots were the ROS regulator genes and extracellular matrix genes that IL-35 regulated. The
large dots were extracellular matrix protein pathways. The bright words, but not dim words, indicated the significance of the pathways.
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inflammatory angiogenesis ROS promoters at early phase. We
also noticed that IL-35 upregulated ROS inhibitor Fbln5 was in
the late regenerative angiogenesis ROS regulator group
(Supplementary Figure 5). Of note, the functions of these four
ROS regulators have been reported as the PMIDs shown in
Figure 6B.
We then hypothesized that these four ROS regulators are
functionally connected to IL-35 upregulation of anti-angiogenic
extracellular matrix proteins revealed by our RNA-Seq. To test
this hypothesis, we used the Cytoscape network integration
database. As shown in Figure 6C, four ROS regulators (small
dots) were functionally connected to extracellular matrix
proteins (also small dots) via ECM pathway network (large
dots). Since we previously demonstrated in the extensive
experiments that IL-35 inhibits ROS generation, and that these
four ROS regulators have been experimentally verified in the
literature (Figure 6B), taken together, these results suggest that
IL-35 inhibition of ROS generation may mediate IL-35
upregulation of anti-angiogenic ECM.
IL-35 Inhibits Human Microvascular EC
Migration and Tube Formation In Vitro
Mainly Through Upregulating Anti-
Angiogenic Extracellular Matrix-
Remodeling Proteins
We hypothesized that IL-35 upregulates anti-angiogenic ECM
proteins not only in transcription levels but also in protein
expression. To demonstrate the direct function of IL-35 to
HMVECs during the angiogenic process, we performed two in
vitro assays, tube formation and wound healing (Figures 6A, B).
Under angiogenic stimuli of fibroblast growth factor 2 (FGF2)
(72), IL-35 significantly reduced HMVEC migration (Figures






FIGURE 7 | IL-35 inhibits human microvascular endothelial cell (HMVEC) migration and tube formation in vitro mainly through upregulating anti-angiogenic
extracellular matrix-remodeling proteins. (A, B) Representative images and statistics of wound healing assay. Scale bar is 500 µm Migration distance (mm) = (db −
da)/2. After starvation with 0.1% FBS overnight, the monolayers of HMVECs were scratched and treated with/without 40 ng/ml of IL-35, 80 ng/ml of FGF2, or both
IL-35 and FGF2 for 12 h. Images were taken at 0 and 12 h. Two individual experiments were combined in (B). (C, D) Representative images and statistics of tube
formation assay. Scale bar is 200 µm. After starvation with 0.1% FBS overnight, HMVECS were seeded on basement membrane extract (BME) and treated with/
without 10 ng/ml of IL-35, or complete culture medium for 5 h. Total master segment length was measured using ImageJ Angiogenesis Analyzer. Two individual
experiments were combined in (D). (E) Three blots of human angiogenesis protein array. After starvation with 0.1% FBS overnight, HMVECs were treated with/
without 80 ng/ml of FGF2, or both 40 ng/ml of IL-35 and FGF2 for 12 h. Proteins were collected and pooled from three biological replicates in each treatment, then
performed proteome profile following the instruction of human angiogenesis array kit. One-way ANOVA with Bonferroni post-test adjustment was used based on two
technical replicates of each protein. IL-35-changed proteins under FGF2 treatment were color-labeled and framed. (F) Normalized expression of IL-35-changed
angiogenic proteins compared to FGF2-treated group. Data from (B, D) are presented as mean ± SEM. *p < 0.05; ***p < 0.001. Data from (F) has no error bar or
statistics because each group only has one pooled sample for the protein array.
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basal level, it could significantly impair tube formation. IL-35-
retarded EC tube formation and migration has been reported in
HUVECs by suppressing Ang2/Tie2 pathway (28); however, we
did not observe the transcriptional changes of Ang2/Tie2 in the
IL-35-treated HLI-isolated mouse ECs. The results showed that
IL-35 inhibited tube formation but not wound healing at the
basal levels (Figures 7C, D), suggesting that IL-35 inhibition of
angiogenesis acts on vessel formation but not on angiogenic cell
migration at basal levels. These results were well correlated with
our results in Figure 3E above that the EGFP+ BM-derived cells
(including potential angiogenic cells) (73) were in high
concentration in vascular areas in the presence of IL-35. To
identity the molecular mechanisms underlying IL-35
suppression of tube formation and FGF2-induced EC
migration, we performed a human protein array assay, which
included 55 angiogenesis-related proteins (Figure 7E). Briefly,
HMVECs were treated with medium only, 80 ng/ml of FGF2, or
both FGF2 and IL-35 (40 ng/ml) for 12 h. Consistent with the
mouse EC RNA-Seq result that most significantly enriched
pathways in IL-35-injected group were related to ECM
organization, this result showed that IL-35 regulated nine
angiogenic proteins, and eight of them (89%) were ECM-
modulating proteins (Figure 7F). Specifically, IL-35 upregulated
several anti-angiogenic proteins, including plasminogen activator
inhibitor 1 (PAI-1), pigment epithelium-derived factor (PEDF)
(confirmed in Supplementary Figure 6), Maspin (a tumor
suppressor), and thrombospondin 1 (THBS-1, an endogenous
inhibitor of angiogenesis). The last three proteins have been
shown to inhibit EC migration directly in vitro (74–76). In
addition, transcriptional changes of the tested genes had similar
extent of increase in both mouse ECs isolated from IL-35-injected
muscle and in IL-35-treated HMVECs. PAI-1 (encoded by
Serpine1) was upregulated by 2.11-fold in mouse ECs and 1.17-
fold in HMVECs; PEDF (encoded by Serpinf1) was upregulated
by 1.34-fold in mouse ECs and 2.28-fold in HMVECs; and Thbs1
was upregulated by 2.03-fold in mouse ECs and 1.15-fold in
HMVECs (HMVEC results from PCR array did not show).
Taken together, IL-35 inhibits angiogenesis largely via the
induction of anti-angiogenic ECM-remodeling regulators in
transcription and protein levels in vitro and in vivo presumably
via a novel mechanism of IL-35 modulation of ROS (Figure 6).
DISCUSSION
PAD affects approximately 20% of adults over the age of 50 (77).
PAD is an aging disease caused by atherosclerosis, where patients
often present impaired angiogenic potential after ischemia.
Inflammatory regulators are critical for post-ischemic
neovascularization. However, sustained inflammation leads to
delayed neovascularization (21) or undesired excessive growth of
blood vessels (22). HLI model is the main preclinical
experimental model for PAD. It has been a powerful model to
study post-ischemic revascularization, postnatal arteriogenesis,
and angiogenesis (44). However, there are several limitations.
First, common complications such as atherosclerosis and
diabetes are not always considered in the animal model, where
in most cases young mice are used for experiments and are
not comparable to aging diseases (53). Second, surgical ligation
in HLI model causes an acute ischemia rather than a chronic
process of vascular narrowing seen in patients (77–79). Diabetic
mice have been shown to present impaired angiogenesis and
recovery from HLI. IL-35 has been reported to inhibit diabetic
neuropathic pain (80). Due to the limited scope of this study, we
were unable to include diabetic conditions into our consideration
(64). Future work is needed to determine the roles of IL-35 in
suppressing diabetic inflammation and modulating diabetes-
impaired angiogenesis. Third, there are variabilities in the
angiogenic processes in different mouse strains (78). Fourth,
we acknowledge that current one stage HLI model (81) would
not allow us to examine the regenerative angiogenesis in details.
Thus, anti-inflammatory treatment has been presumed a
promising therapy to control the local inflammation and
promote desired neovascularization. TGF-b, IL-10, and newly
discovered cytokine IL-35 are three primary anti-inflammatory
cytokines secreted by Tregs, which are the critical
immunosuppressive cells in our body (13, 26, 82, 83). TGF-b is
a multifunctional regulator constitutively expressed in many
tissues (4), while IL-10 and IL-35 are inflammation-induced
anti-inflammatory cytokines (4). This suggests that IL-10 and IL-
35 could be better therapeutic targets in the treatment of chronic
inflammatory diseases. Emerging studies have shown that IL-35
is a more potent anti-inflammatory cytokine in promoting
inducible Treg (50) and Breg (14) than TGF-b and IL-10. In
addition, human Tregs express and require IL-35 for maximal
suppressive function, and activated human Tregs have
substantially upregulated gene expression of EBI3 and IL-12A,
but not IL-10 or TGF-b (84). While TGF-b and IL-10 have been
extensively studied, the role of IL-35 in angiogenesis has not been
thoroughly investigated. It has been shown that IL-35 is
expressed in many tumor cell lines compared to normal cell
lines and promotes tumor angiogenesis and progression (24, 25).
However, one study finds that IL-35 over-expression inhibits
tumor angiogenesis through increasing apoptosis sensitivity and
inhibition of proliferation in human cancer cells (27). In
rheumatoid arthritis (28), it has been demonstrated that IL-35
inhibits angiogenesis. However, the roles of IL-35 in modulating
angiogenesis triggered by HLI remained unknown. Our results
showed that IL-35 therapy delayed inflammatory angiogenesis
phase but did not make a significant difference at regenerative
angiogenesis phase, suggesting that IL-35 therapy made a catch-
up in facilitating the regenerative phase. Future work is required
to determine the molecular and cellular mechanisms underlying
the catch-up and facilitation, which were well correlated with IL-
35 promotion of macrophage survival and improvement of
wound healing after myocardial infarction (85). In addition,
differences between the IL-35 roles in angiogenesis in HLI and
myocardial infarction may also result from potential functions of
cardiokines (86) and myokines (87).
To fill this important knowledge gap, we examined this issue
by using loss-of-function, gain-of-function, omics data analysis,
RNA-Seq, in vivo and in vitro experiments, and we have made
the following significant findings: i) IL-35 and its receptor
subunit IL-12RB2, but not IL-6ST, are induced in the ischemic
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muscle after HLI; ii) HLI-induced angiogenesis is improved in
IL12RB2−/− mice, in ApoE−/−/IL12RB2−/− mice compared to
WT and ApoE−/− controls, respectively, where hyperlipidemia
inhibits angiogenesis in vivo and in vitro; iii) IL-35 cytokine
injection delays blood perfusion recovery at day 14 after HLI; iv)
IL-35 spares regenerative angiogenesis at the late phase of HLI
recovery after 14 dpi; v) Transcriptome analysis of ECs at 14 days
post-HLI reveals a disturbed extracellular matrix re-organization
in IL-35-injected mice; vi) IL-35 downregulates three reactive
oxygen species (ROS) promoters and upregulates one ROS
attenuator, which may functionally mediate IL-35 upregulation
of anti-angiogenic extracellular matrix proteins in ECs; and vii)
IL-35 inhibits human microvascular EC migration and tube
formation in vitro mainly through upregulating anti-
angiogenic extracellular matrix-remodeling proteins. In our
study, we find that IL-35 inhibits ischemia/hypoxia-induced
angiogenesis but spare regenerative angiogenesis. In summary,
IL-35 regulates angiogenesis in a context-dependent manner,
which is similar to the function of TGF-b and IL-10. This
phenomenon may explain some unsatisfied outcome of
CANTOS clinical trial.
The proper angiogenic process in which new blood vessels
sprout from existing ones largely relies on timely regulation of
ECM degradation and synthesis. Our results of GSEA of
CD45−CD31+ ECs, isolated from IL-35-injected ischemic
muscle at 14 dpi, reveal significant enrichment of gene sets
regulating ECM remodeling, including collagen formation,
MMP activation, and integrin b1 and b3 pathways. MMP and
ADAM are the most-studied proteases in angiogenesis.
Collectively, they can degrade all known ECM components.
Our analysis reveals that three MMP genes (Mmp12, Mmp14,
and Mmp19) are induced, and one endogenous inhibitor Timp4
is reduced in IL-35-treated ECs, which indicates an activated
MMP pathway in IL-35-treated ECs at 14 dpi. MMPs are
previously considered as pro-angiogenic mediators (88).
However, it has also been well acknowledged that MMPs are
also the principal proteases responsible for generating potent
angiogenesis inhibitors such as angiostatin and endostatin (89,
90). Among them, MMP12 is potent in generating angiostatin
(91) and endostatin (92) [COL18A1 is increased in IL-35-
injected mouse ECs and IL-35-treated HMVECs (data not
shown)]. Interestingly, there are also significant inductions of
thrombospondin family genes (ECM glycoproteins, Thbs1, and
Thbs2) in IL-35-injected mouse ECs. Thbs1 and Thbs2 have
been well acknowledged as potent endogenous inhibitors of
angiogenesis and tumor growth (93, 94). In addition, THBS1
protein level is elevated in IL-35-treated HMVECs. Collectively,
abnormally activated ECM-remodeling genes at 14 dpi of HLI
may explain the delayed blood flow recovery in IL-35-injected
mice compared to PBS-injected control.
Ingenuity Pathway Analysis (IPA) core analysis of the 341
DEGs in the IL-35-injected mouse EC at 14 dpi predicts five top
upstream regulators (Figure 5C). Among them, predicted
downregulation of a-catenin could lead to 18 downstream
molecules including collagen, and MMPs (Figure 5D). Though
there is no significant change of a-catenin gene expression in IL-
35-treated ECs in mice, it does not exclude the possibility of post-
transcriptional regulation of a-catenin (95). In addition, hypoxia
seems to induce the expression of a-catenin, while IL-35
inhibited the induction (Figure 5E). a-catenin, an actin-
binding protein, is an element of the core complex in
endothelial adherens junctions (AJs). The core complex is
composed of vascular cadherin (VE)-cadherin (transmembrane
protein), p120-catenin, b-catenin or plakoglobin (encoded by
JUP gene), and a-catenin. Thus, we examined other components
in our experiments, and the results showed that JUP (FC = 0.58)
was significantly downregulated in the RNA-Seq data of mouse
EC and VE-cadherin expression on EC was trending down as
well (Figures 5F, G). This cadherin-based AJ regulates the
intracellular actin-myosin network and is essential for vascular
integrity (41). Studies have shown that a-catenin has a critical
role in AJ development (96). Lack of VE-cadherin leads to
increased vascular permeability and impaired endothelial
barrier (42). Also, increased mRNA and protein level of
plakoglobin has been associated with tightly confluent cells in
vitro (97). These results suggest that endothelial AJ is impaired in
the IL-35-injected mouse EC at 14 dpi. As we find in RNA-Seq
result, integrin pathways are significantly enriched, which
indicates an increase of focal adhesion (cell–ECM). Cell–ECM
and cell–cell adhesions are highly integrated networks of protein
interactions. Numerous studies have shown that integrins and
cadherins share many downstream signaling molecules and can
modulate each other in various ways (98, 99). A recent study
shows that integrin can dissociate the VE-cadherin/catenin
complex and disrupt vascular AJ (100). In addition, IL-35
inhibits HMVEC migration through including anti-angiogenic
proteins of pigment epithelium-derived factor (PEDF), Maspin,
and thrombospondin-1 (THBS-1). All three proteins have been
shown to inhibit EC migration in vitro. PEDF is a potent
inhibitor of EC migration under many angiogenic inducers,
including PDGF, VEGF, and IL-8 (74). Maspin, a tumor
suppressor, has been shown to inhibit HUVEC migration
under FGF2 stimulation through an integrin b1 signaling
pathway (75). This study shows that Maspin increases focal
adhesion stability through activation of integrin-linked kinases
and retards EC migration. Besides, THBS-1, an endogenous
inhibitor of angiogenesis which is also induced in IL-35-
injected mouse EC in vivo, inhibits HUVEC migration in an
integrin b1-dependent manner (76). It shows that the type-1
repeat (TSR) domain in THBS-1 can bind to b1 integrins and
inhibit EC migration. Thus, we propose that IL-35-enhanced
integrin-mediated cell–ECM adhesion may lead to the
disassembling (VE-cadherin)–plakoglobin–(a-catenin) complex,
which impairs vascular AJ and EC migration. However, further
experiment should be set up to test this hypothesis.
Based on our and others’ findings, we propose a novel working
model (Figure 8): first, HLI triggered angiogenesis can be classified
into two phases: 1) we define early phase as before the day 14
after HLI surgery based on the data presented in Figure 2B. We
observed a significant improvement of blood supply in ApoE−/−/
IL-12Rb2−/− mice in the day 14 after surgery comparing to that
at the day 7 after surgery but no significant differences between
ApoE KO and ApoE−/−-/IL-12Rb2−/− mice. 2) We observed
that in Figure 3B, two curves converged at day 28 after
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surgery, which indicates that IL-35-treated group has at least
two phases of the effect on the hypoxia phase and recovery
phase after HLI. HLI-created hypoxia triggers inflammatory
angiogenesis at early phase 1 to 14 dpi as judged by
upregulating 18 chemokines and receptors, 23 cytokines, and
receptors. We previously reported a list of 14 proangiogenic
cytokines and chemokines (38). These proangiogenic cytokines/
chemokines were upregulated at the early phase of HLI
(unpublished). Second, HLI induces upregulation of anti-
inflammatory cytokine IL-35, which inhibits inflammatory
angiogenesis by downregulating ROS regulators DDIT4 and
XDH and upregulating anti-angiogenic ECM mechanisms up to
14 dpi. Third, after 14 dpi hypoxia gradually changes to normoxia
at the late phase and regenerative angiogenesis as judged by
upregulating energy metabolism regulators, vessel remodeling to
high efficiency, and blood perfusion restored back to normal;
fourth, out of 165 ROS regulators in the GSEA database, the
expressions of 116 ROS regulators are significantly modulated in
HLI, which can be classified into the early phase inflammatory
angiogenesis ROS regulators (25 regulators upregulated at 3 dpi)
and late phase regenerative angiogenesis ROS regulators (56
regulators upregulated at 7 dpi) (Supplementary Figure 5). IL-
35 spares regenerative angiogenesis after 14 dpi in HLI by anti-
ROS regulator Fbln5, which are well correlated with recent reports
that IL-35 is protective in myocardial infarction-induced injury
(85, 101). Of note, the stronger protection of IL-35 in the cardiac
muscle than in the skeletal muscle may be due to tissue specificity.
In addition, differences between the IL-35 roles in angiogenesis in
HLI and myocardial infarction may also result from potential
functions of cardiokines (86) and myokines (87). These findings
provide a novel insight on the future therapeutic potential of IL-35
in suppressing ischemia/inflammation-triggered inflammatory
angiogenesis at the early phase but sparing regenerative
angiogenesis at the late phase, which is similar to our recent
FIGURE 8 | A new working model: Hypoxia-induced anti-inflammatory cytokine IL-35 inhibits hindlimb ischemia-triggered inflammatory angiogenesis at early phase,
but spare regenerative angiogenesis at late phase.
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report that IL-35 inhibits human aortic endothelial cell activation
triggered by proatherogenic lipids but spare trained immunity
pathway (8).
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SUPPLEMENTARY FIGURE 1 | IL-35 is induced by hypoxia treatment in human
microvascular endothelial cells (HMVECs) and its receptor subunit IL-12RB2, but
not IL-6ST, is increased by IL-35 treatment. (A) Gene expressions of IL-35 subunits
in GSE3313 dataset. Whole muscle RNA was collected from male mice, and
expression levels were compared to that of pre-HLI surgery. (B) Experimental
schematics of hypoxia treatment on HMVECs. After HMVECs were 80% confluent,
the hypoxia group was incubated in a hypoxia chamber (BioSpherix, P110) at 0.2%
O2 for indicated hours. Western blot of hypoxia inducible factor 1 subunit alpha
(HIF1A) protein level was significantly increased after 6-h hypoxia treatment. (C)
Normalized mRNA expression levels of IL-35 and its receptor subunits after 2, 6,
and 24 h of hypoxia treatment. Data are presented as mean ± SEM with individual
points plotted. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
SUPPLEMENTARY FIGURE 2 | IL-35-IL12RB2 signaling inhibits hindlimb
ischemia-induced angiogenesis specially in male mice; male outperforms female
regardless to the treatment or genotype. (A–F) Blood perfusion ratio in HLI model.
Hindlimb blood flow was measured on day post-ischemia (dpi) 0, 3, 7, 14, 21, and
28 using a laser Doppler blood flow analyzer. Blood flow was quantitatively
assessed by the ratio of mean flow signals of the ischemic to the non-ischemic
plantar. Data are presented as mean ± SEMwith individual points plotted. *p < 0.05;
**p < 0.01; ***p < 0.001; ****p < 0.0001.
SUPPLEMENTARY FIGURE 3 | IL-35 inhibits FGF2-induced angiogenesis in
Matrigel plug assay. (A) Schematics of Matrigel plug assay and findings. Blue lines
represented the extracellular matrix, red lines represented blood vessels. (B)
Representative images of the Matrigel plugs (~1.5 cm of diameter attached to the
skin) at 11 days after injection. Images were taken under dissecting microscope.
Black arrows indicated the new blood vessels grown in the Matrigel plug. (C)
Representative images of Matrigel plug stained with anti-CD31 (green), anti-neuron-
glial (NG2, red, a pericyte marker), anti-F4/80 (magenta), and DAPI (blue). White
dashed lines contour the attached skin at below. (D) Statistics of cell count and the
percentage of indicated populations. n = 5. Statistics were based on 45 randomly
selected field of views. Scale bar sized are as indicated in the pictures. All results
were collected from male mice. Data are presented as mean ± SEM with individual
points plotted. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
SUPPLEMENTARY FIGURE 4 | 47 collagen genes are analyzed in RNA-
seq data.
SUPPLEMENTARY FIGURE 5 | The expressions of 116 out of 165 reactive
oxygen species regulators in the GSEA database were significantly changed on the
day 1, day 7, and day 14 after hindlimb ischemia (HLI) in the wild-type male mouse
datasets in the GSE3313 datasets in the NIH Geo Datasets database. The
significantly changed genes were listed in this table and heatmap on the left panel
(As shown in Figure 6B, DDIT4 and XDH shown in blue fonts were suppressed by
IL-35, and FBLN5 shown in red fonts was increased by IL35. TNF was not
significantly changed in the time course).
SUPPLEMENTARY FIGURE 6 | IL-35 induces anti-angiogenic protein of
pigment epithelium-derived factor (PEDF) in human microvascular endothelial cells
(HMVECs). (A, B) Immunoblots and statistics of PEDF expression levels. After
starvation with 0.1% FBS overnight, HMVECs were treated with 40 ng/ml of IL-35
for indicated time. (C, D) Immunoblots and statistics of PEDF expression levels.
After starvation with 0.1% FBS overnight, HMVECs were treated under normoxia, or
hypoxia (0.2% O2) with or without 40 ng/ml of IL-35 for 12 h. Data are presented as
mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
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